How Verve's 'One Shot' Triggered a Remarkable Breakthrough in the Fight to End Heart Disease

GV congratulated Verve Therapeutics on its IPO, describing its earlier Series A leadership and subsequent Series B participation. No complete disposal or realized return is asserted.